699 filings
Page 2 of 35
SC 14D9
oz5ckavlh
26 Jan 18
Tender offer solicitation
12:00am
8-K
r8o ye804s8u
26 Jan 18
Repros Announces Negative Opinion From the EMA for Enclomiphene
12:00am
SC 14D9/A
zv4unl2w5c
19 Jan 18
Tender offer solicitation (amended)
12:00am
SC 14D9/A
qumvw70bx8 1iqry8e
5 Jan 18
Tender offer solicitation (amended)
12:00am
SC TO-T/A
8y1ozpnw 3bz7pvb
5 Jan 18
Third party tender offer statement (amended)
12:00am
SC TO-T/A
s1rfxr t4ny3xb6
4 Jan 18
Third party tender offer statement (amended)
12:00am
SC 14D9/A
hkjddfo
3 Jan 18
Tender offer solicitation (amended)
12:00am
SC 14D9
cil9gliu
29 Dec 17
Tender offer solicitation
12:00am
SC TO-T
uuzphrezq2yzoy
29 Dec 17
Third party tender offer statement
12:00am
8-K
i87m89
15 Dec 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
SC14D9C
wo5fyqzuo8ajztmux5ke
15 Dec 17
Written communication relating to third party tender offer
12:00am
8-K
2u12cn9
15 Dec 17
Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency
12:00am
SC14D9C
spxlizz7za5n048tq
13 Dec 17
Written communication relating to third party tender offer
12:00am
8-K
xmbgub9o13u8j
12 Dec 17
Repros Therapeutics Inc.® Announces Acquisition by Allergan plc
12:00am
8-K
t6m1ix13h4hv
13 Nov 17
Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results
12:00am
8-K
qxbj2v hlefmkxz42v2j
13 Nov 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
ljte9uo0sbwvwdzkl oh
13 Oct 17
Departure of Directors or Certain Officers
12:00am
8-K
k7z63n4nb fx
15 Sep 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
wl2 emqoncq
11 Sep 17
REPROS THERAPEUTICS Corporate Presentation September 2017 Dedicated to Treating Male and Female Reproductive Disorders
12:00am